Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Toxicity Evaluation of a Novel Magnetic Resonance Imaging Marker, CoCl2-N-Acetylcysteine, in Rats.

Wang L, Gagea M, Martirosyan K, Johansen M, Madden T, Norberg L, Culotta KS, Frank SJ.

J Toxicol. 2018 Dec 2;2018:9173452. doi: 10.1155/2018/9173452. eCollection 2018.

2.

Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.

Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R.

Cancer Chemother Pharmacol. 2016 Apr;77(4):881. doi: 10.1007/s00280-016-3002-1.

PMID:
26994910
3.

Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.

Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R.

Cancer Chemother Pharmacol. 2016 Feb;77(2):357-64. doi: 10.1007/s00280-015-2946-x. Epub 2015 Dec 23. Erratum in: Cancer Chemother Pharmacol. 2016 Apr;77(4):881.

PMID:
26698868
4.

An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.

Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Aiyer RA, Maywald RL, Buford AS, Doolittle DK, Culotta KS, O'Dorisio JE, Ludwig JA.

Mol Cancer Ther. 2015 Jul;14(7):1591-604. doi: 10.1158/1535-7163.MCT-14-0334. Epub 2015 May 11.

5.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M.

Clin Cancer Res. 2015 Jun 15;21(12):2704-14. doi: 10.1158/1078-0432.CCR-14-2888. Epub 2015 Feb 27.

6.

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.

Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F.

J Natl Cancer Inst. 2015 Feb 16;107(3). pii: dju493. doi: 10.1093/jnci/dju493. Print 2015 Mar.

7.

Physical and chemical stability of proflavine contrast agent solutions for early detection of oral cancer.

Kawedia JD, Zhang YP, Myers AL, Richards-Kortum RR, Kramer MA, Gillenwater AM, Culotta KS.

J Oncol Pharm Pract. 2016 Feb;22(1):21-5. doi: 10.1177/1078155214546564. Epub 2014 Aug 10.

PMID:
25113309
8.

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.

Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R.

Cancer. 2014 Jul 15;120(14):2164-73. doi: 10.1002/cncr.28701. Epub 2014 Apr 17.

9.

Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion.

Zhang Y, Kawedia JD, Myers AL, McIntyre CM, Anderson PM, Kramer MA, Culotta KS.

J Oncol Pharm Pract. 2014 Feb;20(1):51-7. doi: 10.1177/1078155213478284. Epub 2013 Mar 19.

PMID:
23512269
10.

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.

Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB.

Clin Cancer Res. 2012 Feb 15;18(4):1120-8. doi: 10.1158/1078-0432.CCR-11-2436. Epub 2012 Jan 5.

11.

Busulfan and metronidazole: an often forgotten but significant drug interaction.

Gulbis AM, Culotta KS, Jones RB, Andersson BS.

Ann Pharmacother. 2011 Jul;45(7-8):e39. doi: 10.1345/aph.1Q087. Epub 2011 Jul 5.

PMID:
21730282
12.

Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity.

Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R.

Mol Cancer Ther. 2011 Jul;10(7):1300-7. doi: 10.1158/1535-7163.MCT-11-0259. Epub 2011 May 13.

13.

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.

Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA.

Cancer. 2011 May 15;117(10):2112-9. doi: 10.1002/cncr.25769. Epub 2010 Nov 29. Erratum in: Cancer. 2012 May 1;118(9):2560. Johnson, Faye M [added].

14.

Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.

Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V.

Cancer Prev Res (Phila). 2009 Nov;2(11):931-41. doi: 10.1158/1940-6207.CAPR-09-0121.

15.

T cell CD3 receptor zeta (TCRzeta)-chain expression in children with idiopathic nephrotic syndrome.

Aviles DH, Vehaskari MV, Culotta KS, Manning J, Ochoa AC, Zea AH.

Pediatr Nephrol. 2009 Apr;24(4):769-73. doi: 10.1007/s00467-008-1061-1. Epub 2008 Dec 10.

PMID:
19082633
16.

Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment.

Zea AH, Culotta KS, Ali J, Mason C, Park HJ, Zabaleta J, Garcia LF, Ochoa AC.

J Infect Dis. 2006 Nov 15;194(10):1385-93. Epub 2006 Oct 4.

PMID:
17054067
17.

L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes.

Zea AH, Rodriguez PC, Culotta KS, Hernandez CP, DeSalvo J, Ochoa JB, Park HJ, Zabaleta J, Ochoa AC.

Cell Immunol. 2004 Nov-Dec;232(1-2):21-31. Epub 2005 Feb 23.

PMID:
15922712
18.

L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes.

Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC.

J Immunol. 2003 Aug 1;171(3):1232-9.

19.

Regulation of T cell receptor CD3zeta chain expression by L-arginine.

Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC.

J Biol Chem. 2002 Jun 14;277(24):21123-9. Epub 2002 Apr 11.

Supplemental Content

Loading ...
Support Center